| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/29/2010 | US20100190964 Antibodies to human ErbB4 |
| 07/29/2010 | US20100190962 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 07/29/2010 | US20100190838 Connective Tissue Growth Factor Fragments and Methods and Uses Thereof |
| 07/29/2010 | US20100190725 Amino acid derivatives |
| 07/29/2010 | US20100190724 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 07/29/2010 | US20100190723 Preventive or therapeutic composition for liver disease |
| 07/29/2010 | US20100190722 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 07/29/2010 | US20100190721 Peptide whitening agents and cosmetic compositions comprising the same |
| 07/29/2010 | US20100190720 Compositions and Methods for Preventing or Treating Cancer |
| 07/29/2010 | US20100190719 Peptides as antimicrobial agents towards campylobacter spp |
| 07/29/2010 | US20100190718 Methods for preventing or treating mitochondrial permeability transition |
| 07/29/2010 | US20100190717 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| 07/29/2010 | US20100190716 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 07/29/2010 | US20100190715 Stable Formulations of Peptides |
| 07/29/2010 | US20100190714 RNAi Inhibition of Alpha-ENaC Expression |
| 07/29/2010 | US20100190713 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 07/29/2010 | US20100190712 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine |
| 07/29/2010 | US20100190711 Big gastrin i as a therapeutic agent |
| 07/29/2010 | US20100190710 Il-23 receptor antagonists and uses thereof |
| 07/29/2010 | US20100190709 Angiogenic composition |
| 07/29/2010 | US20100190708 Composition for amelioration of body lipid |
| 07/29/2010 | US20100190707 Novel Bacillus Thuringiensis Gene with Lepidopteran Activity |
| 07/29/2010 | US20100190706 Stable Non-Aqueous Pharmaceutical Compositions |
| 07/29/2010 | US20100190705 Suppression of glial fibrillary acidic protein |
| 07/29/2010 | US20100190704 Structure comprising chitosan and collagen |
| 07/29/2010 | US20100190703 Peptides specific for human blood outgrowth endothelial cells |
| 07/29/2010 | US20100190702 Compositions and Methods of Treating Neoplasia |
| 07/29/2010 | US20100190701 Glucagon/glp-1 receptor co-agonists |
| 07/29/2010 | US20100190700 Methods and compositions for treating hypoglycemic disorders |
| 07/29/2010 | US20100190699 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS |
| 07/29/2010 | US20100190698 Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor |
| 07/29/2010 | US20100190697 Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| 07/29/2010 | US20100190696 Treatment of t-cell mediated diseases |
| 07/29/2010 | US20100190695 Liquid crystal emulsion type pharmaceutical composition containing cyclosporine, and therepeutic method of treating cutaneous disease therewith |
| 07/29/2010 | US20100190694 Methods for identifying patients who will respond well to cancer treatment |
| 07/29/2010 | US20100190693 Method for screening compounds & uses therefor |
| 07/29/2010 | US20100190692 Methods for reducing gnrh-positive tumor cell proliferation |
| 07/29/2010 | US20100190691 Delivery of nucleic acids using cell-penetrating peptides |
| 07/29/2010 | US20100190690 Biomimetic particles and films for pathogen capture and other uses |
| 07/29/2010 | US20100190689 Compositions and methods related to protein displacement therapy for myotonic distrophy |
| 07/29/2010 | US20100190688 Tetrapeptide analogs |
| 07/29/2010 | US20100190687 Pyrimidinone derivatives and methods of use thereof |
| 07/29/2010 | US20100190686 Novel secreted proteins of adipocytes for diagnostic purposes |
| 07/29/2010 | US20100190685 Prognostic factor in sarcoma, and metastasis inhibitor |
| 07/29/2010 | US20100190684 Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity |
| 07/29/2010 | US20100190243 siRNA-MEDIATED GENE SILENCING WITH VIRAL VECTORS |
| 07/29/2010 | US20100190211 IL-18 Receptors |
| 07/29/2010 | US20100190195 Use of Hepatitis B X-Interacting Protein (HBXIP) in Modulation of Apoptosis |
| 07/29/2010 | US20100190176 Tumor suppressor designated ts10q23.3 |
| 07/29/2010 | US20100190169 Single nucleotide polymorphisms predicting cardiovascular disease |
| 07/29/2010 | US20100189819 Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
| 07/29/2010 | US20100189802 Method for treatment of vascular hyperpermeability |
| 07/29/2010 | US20100189801 Drug Delivery Systems and Use Thereof |
| 07/29/2010 | US20100189776 Anti-androgen peptides and uses thereof in cancer therapy |
| 07/29/2010 | US20100189773 5-cyano-4- (pyrrolo [2,3] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| 07/29/2010 | US20100189770 Bioerodible patch |
| 07/29/2010 | US20100189769 Polypeptide Films and Methods |
| 07/29/2010 | US20100189764 Bioactive mesh |
| 07/29/2010 | US20100189758 Coating containing pegylated hyaluronic acid and a pegylated non-hyaluronic acid polymer |
| 07/29/2010 | US20100189757 Drug depot implant designs and methods of implantation |
| 07/29/2010 | US20100189747 Compositions and methods for treating or preventing hiv infection |
| 07/29/2010 | US20100189725 P53 modulator and cancer target |
| 07/29/2010 | US20100189721 Antibody formulations |
| 07/29/2010 | US20100189720 Novel card proteins involved in cell death regulation |
| 07/29/2010 | US20100189718 Molecules with extended half-lives, compositions and uses thereof |
| 07/29/2010 | US20100189715 Humanized monoclonal antibodies that protect against shiga toxin induced disease |
| 07/29/2010 | US20100189713 Use of Semaphorin 6A for Promoting Myelination and Oligodendrocyte Differentiation |
| 07/29/2010 | US20100189709 Elastase inhibitor |
| 07/29/2010 | US20100189708 Hydroxy piperidine derivatives to treat gaucher disease |
| 07/29/2010 | US20100189707 Stable Enzymatic Peracid Generating Systems |
| 07/29/2010 | US20100189706 Polypeptide enzymes that can hydrolyze lignocellulose such as sugarcane bagasse, i.e., for biomass processing, industrial uses such as disinfectants, pharmaceuticals, waste treatment, making biofuels, feeds and foods; bioconversion of lignocellulosic residues into fermentable sugars; heat stability |
| 07/29/2010 | US20100189705 Biological decontamination system |
| 07/29/2010 | US20100189704 Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose |
| 07/29/2010 | US20100189698 Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration |
| 07/29/2010 | US20100189689 Tetrameric Cytokines with Improved Biological Activity |
| 07/29/2010 | US20100189688 Dose forms comprising VX-950 and their dosage regimen |
| 07/29/2010 | US20100189687 Modulators of pharmacokinetic properties of therapeutics |
| 07/29/2010 | US20100189686 Albumin Fusion Proteins |
| 07/29/2010 | US20100189685 Antiviral Drugs for Treatment or Prevention of Dengue Infection |
| 07/29/2010 | US20100189684 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/29/2010 | US20100189683 Pulsatile Dosing of Gossypol for Treatment of Disease |
| 07/29/2010 | US20100189682 Biologically active proteins having increased In Vivo and/or In Vitro stability |
| 07/29/2010 | US20100189681 Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer |
| 07/29/2010 | US20100189680 Methods of Treating Various Cancers Using Melanoma Differentiating Associated Protein-7 |
| 07/29/2010 | US20100189669 Regulation of Mammalian Keratinous Tissue Using Skin and/or Hair Care Actives |
| 07/29/2010 | US20100189657 Intramolecularly quenched fluorochrome conjugates and methods of use |
| 07/29/2010 | US20100189655 Methods for treating headache |
| 07/29/2010 | US20100189649 Monoclonal antibodies to activated erbb family members and methods of use |
| 07/29/2010 | US20100189645 Metal chelators and methods of their use |
| 07/29/2010 | US20100189641 Novel Strategies for Improved Cancer Vaccines |
| 07/29/2010 | DE202010004926U1 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets Pancreatin pellets, especially pancreatin micro pellets |
| 07/29/2010 | DE10392697B4 Extrakt von Peptid-verknüpften Glucanen und Peptid-verknüpfte Clucane mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor und deren Reinigungsverfahren und Verwendungen Extract of peptide-linked glucans and peptide-linked Clucane with detectable oral absorbability from Coriolus versicolor and their cleaning methods and uses |
| 07/29/2010 | CA2788223A1 Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
| 07/29/2010 | CA2750851A1 Systems and methods to facilitate online transactions |
| 07/29/2010 | CA2750582A1 Method for the prophylaxis or treatment of flushing |
| 07/29/2010 | CA2750340A1 Biofilm-removing antimicrobial compositions and uses thereof |
| 07/29/2010 | CA2750035A1 Treatment for obesity |
| 07/29/2010 | CA2748873A1 Methods and compositions based on shiga toxin type 2 protein |
| 07/29/2010 | CA2748593A1 Fgf21 derivatives with albumin binder a-b-c-d-e- and their use |
| 07/29/2010 | CA2747825A1 Stable growth hormone compounds |